Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160043/S095

Resolute Onyx Zotarolimus-Eluting Coronary Stent System

Medtronic Vascular · Decision date Aug 14, 2026

FDA DECISIONP160043/S095

What did the FDA decide?

FDA records P160043/S095 as a supplement to PMA P160043, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 14, 2026.

FDA approval order statement

automation of certain steps in the stent manufacturing process
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Aug 14, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P160043/S095
Regulatory pathway
PMA supplement
Product code
NIQ
Decision code
OK30
Decision date
Aug 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Coronary drug-eluting stent.

Product code
NIQ
FDA device class
3

For the original device and its historical approval scope, see PMA P160043. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P160043 · Original PMA

    RESOLUTE ONYX ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM

  2. P160043/S089 · Related supplement

    Resolute Onyx Zotarolimus-Eluting Coronary Stent System - RX and OTW; Onyx Frontier Zotarolimus-Eluting Coronary Stent S

  3. P160043/S090 · Related supplement

    Onyx Frontier Zotarolimus Eluting Coronary Stent System

  4. P160043/S092 · Related supplement

    Resolute Onyx Zotarolimus-Eluting Coronary Stent System; Onyx Frontier Zotarolimus-Eluting Coronary Stent System Stent S

  5. P160043/S093 · Related supplement

    RESOLUTE ONYX ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM

  6. P160043/S094 · Related supplement

    Resolute Onyx Zotarolimus-Eluting Coronary Stent System; Onyx Frontier Zotarolimus-Eluting Coronary Stent System Stent S

  7. P160043/S095 received

    Application receipt date recorded by FDA.

  8. P160043/S095 · FDA decision

    30-Day Notice

  9. P160043/S096 · Related supplement

    Resolute Onyx Zotarolimus-Eluting Coronary Stent Systems

Timeline entries are records held by MedtechLedger for P160043. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160043

Explore the linked device profile

Other records with product code NIQ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Vascular

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
3576 Unocal Pl., Santa Rosa, CA, 95403

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records